CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its anticipated pipeline goals and financial guidance for 2012. Infinity begins the year with seven clinical trials underway across three programs and expects to report data during the year that will inform the potential paths to registration for each of these programs. Infinity’s programs target areas of tremendous unmet patient need where current treatments are either non-existent or inadequate, such as pancreatic cancer, chondrosarcoma and non-small cell lung cancer.
